Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00356798|
Recruitment Status : Completed
First Posted : July 26, 2006
Last Update Posted : November 9, 2007
|Condition or disease||Intervention/treatment||Phase|
|Influenza||Biological: an inactivated whole virion H5N1 vaccine, adjuvanted||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||120 participants|
|Intervention Model:||Factorial Assignment|
|Official Title:||The Phase-I Clinical Trial Protocol for the Pandemic Inactivated Influenza Vaccine|
|Study Start Date :||December 2005|
|Study Completion Date :||April 2006|
- To evaluate the safety of pandemic inactivated influenza vaccine by different does.
- To evaluate the immunogenicity of pandemic inactivated influenza vaccine by different does.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00356798
|China-Japan Friendship Hospital|
|Beijing, Beijing, China, 100029|
|Principal Investigator:||Jiangtao Lin, MD||China-Japan Friendship Hospital|